Category: New Drugs
-
FDA Approves Reformulated Ranitidine Following Comprehensive Safety Review
The U.S. Food and Drug Administration (FDA) has approved a reformulated ranitidine tablet after a comprehensive safety review addressing prior concerns about N‑nitrosodimethylamine (NDMA) impurity formation; the approval includes updated storage and handling requirements to mitigate impurity risk and preserve product stability. Background and regulatory context Ranitidine, an H2‑receptor antagonist widely used for gastroesophageal reflux…
-
FDA Approves Ziftomenib for Acute Myeloid Leukemia
The treatment landscape for acute myeloid leukemia (AML) has recently seen a significant development with the U.S. Food and Drug Administration (FDA) granting full approval to ziftomenib (Komzifti™) for adult patients diagnosed with relapsed or refractory (R/R) AML who harbor a susceptible NPM1 (Nucleophosmin 1) mutation and have no satisfactory alternative treatment options. This landmark…
-
Breakthrough Cancer Drug With No Detectable Side Effects
A significant nanomedicine breakthrough from Northwestern University, led by Prof. Chad A. Mirkin and documented in the peer-reviewed journal ACS Nano, details the transformation of the chemotherapy agent 5-fluorouracil (5-Fu) into a spherical nucleic acid (SNA) structure. According to both the article and surrounding scientific coverage, this innovation reports unprecedented increases in cancer cell targeting…
-
ADRIANA Pain Medication – A Promising Future Alternative to Opioids
The opioid crisis has devastated communities worldwide, particularly in the United States, where opioid overdoses claimed more than 80,000 lives in 2023 alone.¹ While opioids like morphine and oxycodone remain powerful tools for managing severe pain, their risks —including addiction, overdose, and long-term dependence — have created an urgent need for safer alternatives. Enter ADRIANA…